Drug intelligence / Profile preview

Colla-2

Development stage: Unknown
Lead developer: Jagsonpal Pharmaceuticals
Administration: Oral

Overview

**Colla-2** is an oral fixed-dose joint-health nutraceutical marketed by Jagsonpal for osteoarthritis and musculoskeletal joint support. Each tablet contains collagen peptide type II, chondroitin sulfate, curcumin extract, rose hip extract, and sodium hyaluronate. The formulation is intended to support cartilage and synovial-joint function; its curcumin component is used for anti-inflammatory support, while collagen peptide type II, chondroitin sulfate, and sodium hyaluronate are intended to support joint structure, cushioning, and lubrication. Jagsonpal describes Colla-2 as a comprehensive formulation for osteoarthritis. ([jagsonpal.com](https://www.jagsonpal.com/product-category/orthopaedics/))

Brand names: Colla-2Colla2Colla 2
Other names: Colla 2Colla2Colla-2

Beyond the preview

Go deeper on Colla-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Colla-2.

Explore the full profile